Search Results | Blood | American Society of Hematology

1-20 of 76

2 3 4

Sort by

Sort Order Select

Journal Articles

CXCR4 (CD184) Expression in Pediatric AML Is Associated with Bone Marrow Retention, Specific Disease Characteristics, and Worse Outcomes: A Report of 1004 Patients from the Children's Oncology Group AAML1031 Protocol

Andrew J. Menssen, Chad A. Hudson, Todd A. Alonzo, Robert B. Gerbing, Laura Pardo, Fan-Chi Hsu, Loren L. Lott, Fangyan Dai, Keely Ghiradelli, Yi-Cheng Wang, E. Anders Kolb, Todd M. Cooper, Jessica A. Pollard, Michael R. Loken, Richard Aplenc, Lisa Eidenschink Brodersen, Soheil Meshinchi

Blood (2022) 140 (Supplement 1): 3452–3453.

DOI: https://doi.org/10.1182/blood-2022-163682

Published: 2022

Journal Articles

Final Results of Phase I/II Trial of Mitoxantrone in Combination with Clofarabine (MITCL) in Children with Relapsed/Refractory Acute Leukemia

Jessica C Hochberg, Javier Oesterheld, Aliza Gardenswartz, Liana Klejmont, Jaclyn Basso, Elizabeth Mintzer, Lauren Harrison, Michael J Borowitz, Michael R. Loken, Mitchell S Cairo

Blood (2022) 140 (Supplement 1): 6140–6141.

DOI: https://doi.org/10.1182/blood-2022-167040

Published: 2022

Journal Articles

Targeting FOLR1 in High-Risk CBF2AT3-GLIS2 AML with Stro-002 FOLR1-Directed Antibody-Drug Conjugate

Quy Le, Jenny L. Smith, Thao T. Tang, Sommer Castro, Cynthia Nourigat-Mckay, LaKeisha Perkins, Benjamin J. Huang, Rhonda E. Ries, Amanda R. Leonti, Tiffany A. Hylkema, Laura Pardo, Cristina Abrahams, Kristin Bedard, Arturo Molina, Lisa Eidenschink Brodersen, Michael R. Loken, Soheil Meshinchi

Blood (2021) 138 (Supplement 1): 209.

DOI: https://doi.org/10.1182/blood-2021-153076

Published: 2021

Journal Articles

Endothelial Cell Niche Promotes Leukemic Transformation of Human Cord Blood Stem/Progenitor Cells Expressing CBFA2T3-GLIS2 Oncogenic Fusion

Quy Le, Tiffany A. Hylkema, Sommer Castro, Jenny L. Smith, Amanda R. Leonti, Thao T. Tang, Cynthia Nourigat-Mckay, LaKeisha Perkins, Laura Pardo, Lisa Eidenschink Brodersen, Michael R. Loken, Rhonda E. Ries, Keith R. Loeb, Soheil Meshinchi

Blood (2021) 138 (Supplement 1): 360.

DOI: https://doi.org/10.1182/blood-2021-148916

Published: 2021

Journal Articles

Therapeutic Targeting of CD74 with STRO-001 Antibody-Drug Conjugate in AML and ALL

Quy Le, Amanda R. Leonti, Thao T. Tang, Sommer Castro, Cynthia Nourigat-Mckay, LaKeisha Perkins, Rhonda E. Ries, Jenny L. Smith, Tiffany A. Hylkema, Laura Pardo, Cristina Abrahams, Kristin Bedard, Arturo Molina, Lisa Eidenschink Brodersen, Michael R. Loken, Soheil Meshinchi

Blood (2021) 138 (Supplement 1): 509.

DOI: https://doi.org/10.1182/blood-2021-151160

Published: 2021

Journal Articles

Increased Expression of CD56 on Plasmacytoid Dendritic Cells in Myeloid Leukemia Associated with Down Syndrome (ML-DS) Is Normal Regeneration and Not Measurable Residual Disease

Chad A Hudson, Laura Pardo, Loren L. Lott, Michael R. Loken, Lisa Eidenschink Brodersen

Blood (2021) 138 (Supplement 1): 3433.

DOI: https://doi.org/10.1182/blood-2021-149873

Published: 2021

Journal Articles

Epigenetic Silencing of CD34 in AML and Association with Outcome in KMT2A Fusions

Rhonda E. Ries, Lisa Eidenschink Brodersen, Laura Pardo, Timothy Junius Triche, Jr., Amanda R. Leonti, Jenny L. Smith, Todd A. Alonzo, Jason E Farrar, Yi-Cheng Wang, Alice Dang, Alan S. Gamis, Richard Aplenc, E. Anders Kolb, Michael R. Loken, Soheil Meshinchi

Blood (2021) 138 (Supplement 1): 802.

DOI: https://doi.org/10.1182/blood-2021-149210

Published: 2021

Journal Articles

Project Stella: Development and Preclinical Assessment of FOLR1-Directed Chimeric Antigen Receptor T Cells in CBF2AT3-GLIS2/RAM AML

Quy Le, Sommer Castro, Thao T. Tang, Cynthia Nourigat-Mckay, LaKeisha Perkins, Tiffany A. Hylkema, Laura Pardo, Jenny L. Smith, Amanda R. Leonti, Rhonda E. Ries, Lisa Eidenschink Brodersen, Michael R. Loken, Soheil Meshinchi

Blood (2021) 138 (Supplement 1): 2788.

DOI: https://doi.org/10.1182/blood-2021-151836

Published: 2021

Journal Articles

CEBPA -bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children’s Oncology Group

Katherine Tarlock, Adam J. Lamble, Yi-Cheng Wang, Robert B. Gerbing, Rhonda E. Ries, Michael R. Loken, Lisa Eidenschink Brodersen, Laura Pardo, Amanda Leonti, Jenny L. Smith, Tiffany A. Hylkema, William G. Woods, Todd M. Cooper, E. Anders Kolb, Alan S. Gamis, Richard Aplenc, Todd A. Alonzo, Soheil Meshinchi

Blood (2021) 138 (13): 1137–1147.

DOI: https://doi.org/10.1182/blood.2020009652

Published: 2021

Includes: Supplemental data

Journal Articles

Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children's Oncology Group AAML1031 Protocol

Lisa Eidenschink Brodersen, PhD, Chad A. Hudson, MDPhD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Laura Pardo, Amanda R. Leonti, MS, Timothy P. Singleton, MD, Fan-Chi Hsu, PhD, Loren L. Lott, Fangyan Dai, Keely Ghiradelli, E. Anders Kolb, MD, Todd M. Cooper, DO, Jessica A. Pollard, MD, Michael R. Loken, PhD, Richard Aplenc, MD PhD, Soheil Meshinchi, MDPhD

Blood (2020) 136 (Supplement 1): 39.

DOI: https://doi.org/10.1182/blood-2020-142659

Published: 2020

Journal Articles

Therapeutic Targeting of Mesothelin in Acute Myeloid Leukemia with Chimeric Antigen Receptor T Cell Therapy

Quy Le, PhD, Sommer Castro, BS, Thao T. Tang, Anisha Loeb, BA, Amanda R. Leonti, MS, Laura Pardo, Michael R. Loken, PhD, Colin Correnti, PhD, Soheil Meshinchi, MDPhD

Blood (2020) 136 (Supplement 1): 11.

DOI: https://doi.org/10.1182/blood-2020-143140

Published: 2020

Journal Articles

CBFA2T3-GLIS2 induces Malignant Transformation of Primitive CD34+ Cord Blood Cells and Recapitulates Infant Megakaryocytic Leukemia

Tiffany A. Hylkema, BS, Laura Pardo, Keith R. Loeb, MD, Quy Le, PhD, Suzan Imren, MD, Lisa Eidenschink Brodersen, PhD, Michael R. Loken, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 1444.

DOI: https://doi.org/10.1182/blood-2019-126185

Published: 2019

Journal Articles

Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Adam J. Lamble, MD, Lisa Eidenschink Brodersen, PhD, Todd A. Alonzo, PhD, Jim Wang, Robert B. Gerbing, Laura Pardo, Lillian Sung, MD PhD, Sarah K. Tasian, MD, Todd M Cooper, DO, E. Anders Kolb, MD, Richard Aplenc, MD PhD, Michael R. Loken, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 459.

DOI: https://doi.org/10.1182/blood-2019-124587

Published: 2019

Journal Articles

Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031

Jessica A. Pollard, MD, Todd A. Alonzo, PhD, Patrick A. Brown, MD, Robert B. Gerbing, Elizabeth Fox, MD, John Kim Choi, MD, Brian T. Fisher, DO, MSCE, Betsy A Hirsch, PhD, Samir Kahwash, MD, John E. Levine, MDMS, Michael R. Loken, PhD, Susana C. Raimondi, PhD, Katherine Tarlock, MD, Andrew C. Wood, MBCHB, Lillian Sung, MD PhD, Anders E. Kolb, MD, Alan S Gamis, MD MPH, Soheil Meshinchi, MD PhD, Richard Aplenc, MD PhD

Blood (2019) 134 (Supplement_1): 292.

DOI: https://doi.org/10.1182/blood-2019-129557

Published: 2019

Journal Articles

Outcomes Following Allogeneic Stem Cell Transplantation for AML in First Completion Remission Are Comparable between MRD Negative Patients and MRD Positive Patients Receiving Induction Only and Are Superior to MRD Positive Patients Receiving Induction and Additional Therapy

Jonathan A Gutman, MD, Prashant Sharma, MD, Enkhtsetseg Purev, MD, Clayton Smith, MD, Amanda Winters, MD PhD, Andrew Hammes, MS, Michael R. Loken, PhD, Daniel A Pollyea, MD

Blood (2019) 134 (Supplement_1): 4615.

DOI: https://doi.org/10.1182/blood-2019-129150

Published: 2019

Journal Articles

High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction

Johann K. Hitzler, MD, Jason Berman, MD, Robert B. Gerbing, Amy Beckman, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Todd E Druley, MD PhD, Michael R. Loken, PhD, Lisa Eidenschink Brodersen, PhD, Karen Chisholm, Shelton A. Viola, MD, Jeffrey W. Taub, MD, Alan S Gamis, MD MPH, Todd A. Alonzo, PhD, E. Anders Kolb, MD

Blood (2019) 134 (Supplement_1): 118.

DOI: https://doi.org/10.1182/blood-2019-126723

Published: 2019

Journal Articles

A Distinct Oncofetal B-Cell Transcriptional Program Is Activated in Infant Acute Myeloid Leukemia and Reveals Novel Therapeutic Strategies

Hamid Bolouri, PhD, Benjamin K. Johnson, PhD, Rhonda E. Ries, MA, Laura Pardo, Tiffany A. Hylkema, BS, Wanding Zhou, PhD, Jenny L. Smith, MSc, MD, Amanda R. Leonti, MS, Allison Kaeding, MD, Michael R. Loken, PhD, Jason E. Farrar, MD, Soheil Meshinchi, MD PhD, Timothy Junius Triche, Jr., PhD

Blood (2019) 134 (Supplement_1): 3768.

DOI: https://doi.org/10.1182/blood-2019-123487

Published: 2019

Journal Articles

Transcriptome Profiling of Glycosylation Genes Defines Correlation with E-Selectin Ligand Expression and Clinical Outcome in AML

Amanda R. Leonti, MS, Laura Pardo, Todd A. Alonzo, PhD, Robert B. Gerbing, Lisa Eidenschink Brodersen, PhD, Rhonda E. Ries, MA, Jenny L. Smith, MSc, MD, Quy Le, PhD, Richard Aplenc, MD PhD, E. Anders Kolb, MD, John L. Magnani, PhD, William E. Fogler, PhD, Michael R. Loken, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 3772.

DOI: https://doi.org/10.1182/blood-2019-124525

Published: 2019

Journal Articles

CD117 Expression Is Associated with Cytogenetic and Molecular Profiles and Outcome in Pediatric Acute Myeloid Leukemia

Katherine Tarlock, MD, Lisa Eidenschink Brodersen, PhD, Todd A. Alonzo, PhD, Yi-Cheng Wang, Robert B. Gerbing, Laura Pardo, Fangyan Dai, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD, Jessica A. Pollard, MD, Michael R. Loken, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 2699.

DOI: https://doi.org/10.1182/blood-2019-127100

Published: 2019

Journal Articles

Indoximod Combined with Standard Induction Chemotherapy Is Well Tolerated and Induces a High Rate of Complete Remission with MRD-Negativity in Patients with Newly Diagnosed AML: Results from a Phase 1 Trial

Ashkan Emadi, MD PhD, Vu H. Duong, MD, Jeremy Pantin, MD, Mohammad Imran, MD, Rima Koka, MD PhD, Zeba Singh, MBBS, Edward A. Sausville, MD PhD, Jennie Y. Law, MD, Seung Tae Lee, MD PhD, Huidong Shi, PhD, Ravindra Kolhe, MD PhD, Maria R. Baer, MD, Michael R. Loken, PhD, Eugene P. Kennedy, MD, Charles Link, MD, David H. Munn, MD

Blood (2018) 132 (Supplement 1): 332.

DOI: https://doi.org/10.1182/blood-2018-99-117433

Published: 2018

2 3 4

NARROW

CXCR4 (CD184) Expression in Pediatric AML Is Associated with Bone Marrow Retention, Specific Disease Characteristics, and Worse Outcomes: A Report of 1004 Patients from the Children's Oncology Group AAML1031 Protocol

Final Results of Phase I/II Trial of Mitoxantrone in Combination with Clofarabine (MITCL) in Children with Relapsed/Refractory Acute Leukemia

Targeting FOLR1 in High-Risk CBF2AT3-GLIS2 AML with Stro-002 FOLR1-Directed Antibody-Drug Conjugate

Endothelial Cell Niche Promotes Leukemic Transformation of Human Cord Blood Stem/Progenitor Cells Expressing CBFA2T3-GLIS2 Oncogenic Fusion

Therapeutic Targeting of CD74 with STRO-001 Antibody-Drug Conjugate in AML and ALL

Increased Expression of CD56 on Plasmacytoid Dendritic Cells in Myeloid Leukemia Associated with Down Syndrome (ML-DS) Is Normal Regeneration and Not Measurable Residual Disease

Epigenetic Silencing of CD34 in AML and Association with Outcome in KMT2A Fusions

Project Stella: Development and Preclinical Assessment of FOLR1-Directed Chimeric Antigen Receptor T Cells in CBF2AT3-GLIS2/RAM AML

CEBPA -bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children’s Oncology Group

Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children's Oncology Group AAML1031 Protocol

Therapeutic Targeting of Mesothelin in Acute Myeloid Leukemia with Chimeric Antigen Receptor T Cell Therapy

CBFA2T3-GLIS2 induces Malignant Transformation of Primitive CD34+ Cord Blood Cells and Recapitulates Infant Megakaryocytic Leukemia

Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031

Outcomes Following Allogeneic Stem Cell Transplantation for AML in First Completion Remission Are Comparable between MRD Negative Patients and MRD Positive Patients Receiving Induction Only and Are Superior to MRD Positive Patients Receiving Induction and Additional Therapy

High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction

A Distinct Oncofetal B-Cell Transcriptional Program Is Activated in Infant Acute Myeloid Leukemia and Reveals Novel Therapeutic Strategies

Transcriptome Profiling of Glycosylation Genes Defines Correlation with E-Selectin Ligand Expression and Clinical Outcome in AML

CD117 Expression Is Associated with Cytogenetic and Molecular Profiles and Outcome in Pediatric Acute Myeloid Leukemia

Indoximod Combined with Standard Induction Chemotherapy Is Well Tolerated and Induces a High Rate of Complete Remission with MRD-Negativity in Patients with Newly Diagnosed AML: Results from a Phase 1 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only